NCT00121628View on ClinicalTrials.gov

A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

November 30, 2006

Study Completion Date

October 31, 2010

Conditions
Thyroid Cancer
Interventions
DRUG

AMG 706

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY